Related Experiment Videos
Alternating chemotherapy in advanced gastric cancer. A phase II study
J Feliu1, C G Girón, M González-Baron
1S. Oncología Médica, H. La Paz, U.A.M. Madrid, Spain.
Cancer Chemotherapy and Pharmacology
|January 1, 1991
Summary
This phase II study evaluated an alternating chemotherapy regimen for advanced gastric cancer. The treatment showed a low response rate and severe toxicities, concluding it is not suitable for gastric cancer treatment.
Area of Science:
- Oncology
- Medical Oncology
- Clinical Cancer Research
Background:
- Advanced gastric cancer presents a significant therapeutic challenge.
- The development of effective chemotherapy regimens is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and toxicity of an alternating chemotherapeutic regimen in patients with advanced gastric cancer.
Main Methods:
- A phase II study involving 22 patients with advanced gastric cancer.
- Treatment included an alternating schedule of cisplatin, mitomycin C, BCNU (Carmustine), doxorubicin, and daily tegafur.
- The regimen was repeated every four weeks.
Main Results:
- An overall response rate of 25% was observed (2 complete and 3 partial responses).
- Remissions were short-lived, with a median survival of 7 months for the entire patient group.
- Severe hematological and gastrointestinal toxicities were reported.
Conclusions:
- The evaluated alternating chemotherapy regimen demonstrated a low response rate in advanced gastric cancer.
- High toxicity associated with the regimen limits its clinical applicability.
- This treatment strategy is not recommended for the management of advanced gastric cancer.